WHO Releases Updated 2024 Bacterial Priority Pathogens List to Tackle Global Antimicrobial Resistance

WHO Updates Global List of Bacterial Priority Pathogens for 2024: Why It Matters for Public Health

Antimicrobial resistance (AMR) remains one of the most urgent health threats of our time, claiming over 1.27 million lives annually. To guide research, investment, and policy, the World Health Organization (WHO) has released the updated Bacterial Priority Pathogens List (BPPL) 2024, published in The Lancet Infectious Diseases.

This revised list builds on the 2017 version and incorporates new global data, refined methodology, and expert consensus to identify the bacteria that pose the most significant threat to human health.

What is the WHO Bacterial Priority Pathogens List?

The BPPL is a global tool that ranks antibiotic-resistant bacteria based on criteria such as:

Mortality and disease burden
Resistance trends over the past decade
Treatability and effectiveness of existing antibiotics
Transmissibility and preventability
Status of the antibiotic development pipeline

Using this evidence-based framework, the 2024 BPPL categorizes pathogens into three tiers: Critical, High, and Medium priority.

Key Findings of the 2024 BPPL

Critical Priority Pathogens
- Carbapenem-resistant Klebsiella pneumoniae (ranked highest at 84%)
- Carbapenem-resistant Acinetobacter baumannii
- Rifampicin-resistant Mycobacterium tuberculosis
- Third-generation cephalosporin-resistant Enterobacterales
High Priority Pathogens
- Fluoroquinolone-resistant Salmonella enterica serotype Typhi (71%)
- Shigella spp. (70%)
- Neisseria gonorrhoeae (64%)
- Methicillin-resistant Staphylococcus aureus (MRSA, 59%)
- Vancomycin-resistant Enterococcus faecium (69%)
- Carbapenem-resistant Pseudomonas aeruginosa
Medium Priority Pathogens
- Macrolide-resistant Streptococcus pyogenes
- Penicillin-resistant Streptococcus agalactiae (group B strep)
- Ampicillin-resistant Haemophilus influenzae

Why This Matters

The updated list underscores three critical realities:

Gram-negative bacteria remain the biggest AMR threat. These pathogens often show resistance to last-resort antibiotics.
Community-acquired infections are a rising concern. Salmonella, Shigella, and N. gonorrhoeae highlight how resistant pathogens spread beyond hospitals.
The antibiotic pipeline is weak. Despite 13 new approvals since 2017, most are modifications of existing drugs, not truly novel classes.

Implications for Research, Policy, and Health Systems

The 2024 BPPL is not just a ranking—it’s a roadmap. WHO calls for:

Greater investment in R&D for novel antibiotics and alternative therapies
Stronger infection prevention and control measures worldwide
Improved vaccine coverage to reduce reliance on antibiotics
Equitable access to existing treatments in low- and middle-income countries

This framework will guide funding, surveillance, and innovation strategies in the fight against antimicrobial resistance.

Conclusion

The WHO Bacterial Priority Pathogens List 2024 reinforces that AMR is a global crisis demanding urgent, coordinated action. By highlighting the most dangerous pathogens, this updated list provides governments, researchers, and health systems with a clear roadmap to direct resources where they are needed most.

Without decisive action, resistant infections will continue to undermine modern medicine, putting millions of lives at risk.

References

Sati, H., Carrara, E., Savoldi, A., Hansen, P., Garlasco, J., Campagnaro, E., … & Nyaruhirira, A. U. (2025). The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. The Lancet infectious diseases. 10.1016/S1473-3099(25)00118-5